 |
|
|
| |
Switch to TDF: lipoatrophy, bones, lipids
|
| |
| |
"Improvement in Lipoatrophy and Lipid Abnormalities Following Switch from Stavudine (d4T) to Tenofovir DF (TDF) in Combination with Lamivudine (3TC) and Efavirenz (EFV) in HIV-Infected Patients: a 48-Week Follow-Up from Study 903E"
Reported by Jules Levin
IAS-Rio Poster# TuPe2.2B12
JVR Madruga1, I Cassetti2, JMAH Suleiman3, L Zhong4, J Enejosa4, and A Cheng4 for the 903E Study Team
1Centro de Referencia e Treinamento DST/AIDS, Sao Paulo, Brazil;
2Fundacion Centro Estudios Infectologicos, Buenos Aires, Argentina;
3Instituto de Infectologia Emilio Ribas, Sao Paulo, Brazil;
4Gilead Sciences, Foster City, California, USA
Study 903 initially randomized patients to d4T or tenofovir with 3TC/EFV. Data obtained from patients participating in 903E who substituted d4T
to TDF were analyzed. Switching d4T to TDF resulted in:
--significant decreases in serum triglycerides, cholesterol and LDL-C through Week 48 in Study 903E
--Significant improvement in limb fat was observed 48 weeks after switching d4T to TDF
--No changes in spine BMD and small decreases in hip BMD were seen after switching d4T to TDF
--Virologic suppression was maintained 48 weeks after switching d4T to TDF
Patient Disposition Through Week 192
_ 85 patients in the d4T arm substituted d4T to TDF
_ 2 patients withdrew consent and discontinued from the study
_ No patient discontinued study due to adverse events
Demographic and HIV Characteristics (Prior to Switch)
|
|
| |
|
|
|
|
|
